2023 / 03

Next Paper
DOI: 10.47183/mes.2023.033

ORIGINAL RESEARCH

Initial administration of β2-agonists reduces the risk of bronchospasm caused by β1-blockers in comorbid cardiorespiratory pathology

Smolyakova EV1,2, Sinitsyn EA2, Zykov KA1,2
About authors

1 Evdokimov Moscow State Medical and Biological University of the Ministry of Health of Russia, Moscow, Russia

2 Pulmonology Research Institute, Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Ekaterina V. Smolyakova
Orekhovy bulvar, 28, 115682, Moscow, Russia; ur.liam@kavokayloms

About paper

Author contribution: Smolyakova EV — recruitment of patients, processing of the results, article authoring; Sinitsyn EA — discussion of the results; Zykov KA — patient treatment management, discussion of the study results, article authoring.

Compliance with ethical standards: the study was approved by the Ethics Committee of the National Medical Research Center for Cardiology named after academician Yevgeniy Chazov of the Ministry of Health of the Russian Federation (Minutes № 220 of October 31, 2016)

Received: 2023-07-21 Accepted: 2023-09-04 Published online: 2023-09-28
|
  1. World Health Organization. 2022. Available from: https://www.who.int.
  2. Ingebrigtsen TS, Marott JL, Vestbo J, Nordestgaard BG, Lange P. Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. BMJ Open Respir Res. 2020; 7 (1): e000470. DOI: 10.1136/bmjresp-2019-000470. PMID: 33371008; PMCID: PMC7011896.
  3. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018; 27 (149): 180057. DOI: 10.1183/16000617.0057-2018. Erratum in: Eur Respir Rev. 2018; 27 (150): PMID: 30282634; PMCID: PMC9488649.
  4. Shnoda M, Gajjar K, Ivanova V. COPD and Cardiovascular Disease: A Review of Association, Interrelationship, and Basic Principles for Integrated Management. Crit Care Nurs Q. 2021; 44 (1): 91–102. DOI: 10.1097/CNQ.0000000000000342. PMID: 33234862.
  5. Arcoraci V, Squadrito F, Rottura M, Barbieri MA, Pallio G, Irrera N, et al. Beta-Blocker use in older hospitalized patients affected by heart failure and chronic obstructive pulmonary disease: an Italian survey from the REPOSI register. Front Cardiovasc Med. 2022; 9: 876693. DOI: 10.3389/fcvm.2022.876693. PMID: 35651906; PMCID: PMC9149000.
  6. Nebieridze DV. Aktual'nye voprosy primeneniya β-adrenoblokatorov v razlichnyh klinicheskih situaciyah. Medicinskij sovet. 2018; 12: 12–17. DOI 10.21518/2079-701X-2018-12-12-17. Russian.
  7. GOLD, 2023. Available from: https://goldcopd.org/2023-gold-report-2/.
  8. GINA, 2023. Available from: https://ginasthma.org/2023-ginamain-report/.
  9. Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis. 2004; 47: 11–33.
  10. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 2000; 55 (8): 650–6. DOI: 10.1136/thorax.55.8.650. PMID: 10899240; PMCID: PMC1745819.
  11. Yang YL, Xiang ZJ, Xiang RL. Increasing the prescription rate of β-blockers is beneficial for patients with chronic obstructive pulmonary and cardiovascular disease. Eur Heart J. 2021; 42 (34): 3409. DOI: 10.1093/eurheartj/ehab239. PMID: 33948636.
  12. Gulea C, Quint JK, Zakeri R. Clinical and methodological considerations when interpreting meta-analyses of beta-blocker use in patients with chronic obstructive pulmonary disease. Eur Heart J. 2021; 42 (34): 3407–8. DOI: 10.1093/eurheartj/ehab217. PMID: 33948644.
  13. Santus P, Radovanovic D, Di Marco S, et al. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1917–23.
  14. Cazzola M, Mantero A, Santus P, et al. Doppler echocardiographic assessment of the effects of inhaled long-acting β2-agonists on pulmonary artery pressure in COPD patients. Pulm Pharmacol Ther. 2007; 20: 258–64.
  15. Smolyakova EV. Vliyanie terapii selektivnym β1-adrenoblokatorom i β2-agonistom na izmenenie harakteristik β-adrenoreceptorov u pacientov s kardiorespiratornoj patologiej (dissertaciya). 2019. Russian.
  16. GINA, 2017. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2017-GINA.pdf.
  17. GOLD, 2017. Available from: https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf.
  18. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One. 2014; 9 (11): e113048. DOI: 10.1371/journal.pone.0113048.
  19. Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Betablocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res. 2021; 22 (1): 64. DOI: 10.1186/s12931-021-016618. PMID: 33622362; PMCID: PMC7903749.
  20. Nazarov BM. Izuchenie bezopasnosti i ehffektivnosti lecheniya selektivnym β-adrenoblokatorom bol'nyh s serdechnososudistymi zabolevaniyami v sochetanii s bronhoobstruktivnymi zabolevaniyami (dissertaciya). 2014. Russian.